Murchinson’s Novavax NVAX Stock Holding History

Murchinson’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,000	Closed	-$480K	–	94
2023 Q4	$480K	Sell	100,000 -100,000	-50%	-$612K	0.08%	32
2023 Q3	$1.45M	Buy	+200,000	New	+$1.6M	0.19%	33

Other funds holding NVAX

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return

Murchinson's NVAX Position: Q1 2024 in Review

Murchinson sold out of Novavax (NVAX) in Q1 2024, closing a stake of 100,000 shares — an estimated $480K sold.

Murchinson first reported a position in NVAX in Q3 2023 and held it in 2 quarters. The position peaked at $1.45M in Q3 2023. 202 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

Murchinson reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
Murchinson sold 100,000 Novavax shares in Q1 2024, an estimated $480K.
Murchinson first reported a position in Novavax in Q3 2023 and held it in 2 quarters.
Murchinson's Novavax position peaked at $1.45M in Q3 2023.
202 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Murchinson's 13F filing for Q1 2024, filed 15 May 2024.